The current PE ratio of NVCR can't be determined, as the TTM EPS of -$1.39 is negative. The most recent PE ratio recorded for NovoCure was 1101.5 in March 2021.
Over the last nine years, the average PE ratio of NovoCure has been 609.94. Over the past nine years, NVCR's PE ratio was at its highest in the Mar 2021 quarter at 1,101.5, with a price of $132.18 and an EPS of $0.12. The Sep 2016 quarter recorded the bottom point at 6.83, with a price of $8.54 and an EPS of $1.25.
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | 865.2 | N/A |
2019 | N/A | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
NBIX Neurocrine Biosciences Inc | 35.08 | $13.71B |
NVAX Novavax Inc | N/A | $1.39B |
NVCR NovoCure Ltd | N/A | $3.33B |
The current price to earnings ratio of NVCR can't be calculated, as its EPS of -$1.39 is negative.
Over the last 5 years, the average price to earnings ratio for NVCR stock is 730.56.
The highest quarterly PE ratio in the last nine years has been 1,101.5 and it was in the Mar 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.